background: A large number of studies have contributed to understanding the general mechanisms driving ovarian folliculogenesis in humans and show a complex endocrine dialog between the central nervous system, the pituitary and the ovary, integrated by various intraovarian paracrine messages. The role of intraovarian paracrine regulation has acquired more relevance in the recent years owing to the discovery of previously unknown factors, such as the oocyte-derived bone morphogenetic protein (BMP)15. Human Reproduction Update, Vol.20, No.6 pp. 869-883, 2014 Advanced Access publication on June 30, 2014 doi:10.1093/humupd/dmu036 results: The biological actions of BMP15 include: (i) the promotion of follicle growth and maturation starting from the primary gonadotrophin-independent phases of folliculogenesis; (ii) the regulation of follicular granulosa cell (GC) sensitivity to FSH action and the determination of ovulation quota; (iii) the prevention of GC apoptosis and (iv) the promotion of oocyte developmental competence. The existence of biologically active heterodimers with GDF9, and/or the synergistic co-operation of BMP15 and GDF9 homodimers are indeed relevant in this context. Experimental disruption of the bmp15 gene in mice resulted in a mild fertility defect limited to females, whereas natural missense mutations in ewes cause variable phenotypes (ranging from hyperprolificacy to complete sterility) depending on a fine gene dosage mechanism also involving GDF9. Strong evidence supports the concept that such a mechanism plays an important role in the regulation of ovulation rate across mammalian and non-mammalian species. Following the discovery of sheep fecundity genes, several research groups have focused on alterations in human BMP15 associated with primary ovarian insufficiency (POI) or polycystic ovary syndrome. Several variants of BMP15 are significantly associated with POI supporting their pathogenic role, but the underlying biological mechanism is still under investigation and of great interest in medicine. BMP15 maps to the Xp locus involved in the determination of the ovarian defect in Turner syndrome and significantly contributes to the determination of ovarian reserve. Pioneering studies in women undergoing controlled ovarian stimulation indicate that BMP15 may represent a marker of ovarian response or oocyte quality.
Introduction
Ovarian folliculogenesis is central for female fertility and is finely tuned by a complex endocrine dialog between the central nervous system, the pituitary and the ovary. In this context, the intraovarian paracrine messages are fundamental in the modulation of oocyte and follicle growth and maturation, and provide the adequate sensitivity to gonadotrophin stimulation. The network of signals exchanged between the oocyte and the surrounding granulosa cells (GCs) is far from being fully understood, but in recent years several of these signals have been discovered, thus opening previously unpredicted insights on this extraordinary biological process. The end-point of ovarian folliculogenesis is to deliver a competent female gamete with an adequate genetic component. Therefore, the messages originating from the oocyte should be pivotal and indeed orchestrate the formation of primordial follicles and control the subsequent follicular maturation. In this paracrine context, several members of the transforming growth factor b (TGFb) superfamily are now known to play an essential role. In this review, we will focus on the evidence that supports the oocyte-derived bone morphogenetic protein 15 (BMP15) as a critical signal promoting the growth and differentiation of ovarian follicles , whose action is intrinsically linked to the other important oocyte-derived growth and differentiation factor 9 (GDF9). Interestingly, alterations in the BMP15 and GDF9 genes are associated with different ovarian phenotypic abnormalities. Depending on the species, the phenotypes vary from sterility to increased prolificacy in ewes, slight subfertility to sterility in female mouse and primary ovarian insufficiency (POI) to polycystic ovary syndrome (PCOS) in women.
Methods
A thorough literature search was carried out in order to summarize what has been reported on the role of BMP15 in ovarian function and female fertility. Research articles published in English until March 2014 were selected using the following terms: BMP15, GDF9, ovary and primary ovarian insufficiency.
BMP15 gene
The BMP15 gene (OMIM 300247) maps on the X chromosome at Xp11.22. Studies of the X chromosome breakpoints detected in patients with Turner syndrome (TS) revealed the existence of three distinct loci, two on the Xq (Xq13-q21 and Xq23-q27) and the BMP15 locus on the Xp, which are significantly associated with the ovarian phenotype (Toniolo, 2006; Persani et al., 2009) . The BMP15 gene comprises two exons and the major site of expression is in oocytes within the ovary (Dube et al., 1998) , as observed for the GDF9 gene (OMIM 301918) located on HSA5 chromosome (McPherron and Lee, 1993; McGrath et al., 1995) . However, the BMP15 cDNA was cloned from testes (Di Pasquale et al., 2004) and its expression was also demonstrated in the pituitary (Otsuka and Shimasaki, 2002) . A recent phylogenetic analysis indicates that the BMP15 and GDF9 genes diverged very early and exhibited a rapid evolution compared with other BMP members. However, only BMP15 was submitted to a positive selection pressure in the hominidae clade (Auclair et al., 2013) . Expression of the BMP15 gene in oocytes is repressed by the germ cell nuclear factor (also named NR6A1) (Lan et al., 2003) , which binds to the BMP15 promoter, and by the Kit Ligand (KITLG) through binding to KIT receptors on the oocyte membrane (Fig. 1 ).
BMP15 protein
Primary sequence alignment confirms that BMP15 belongs to the TGFb superfamily of cytokines due to the presence of the family characteristic 'cystine-knot' motif (McDonald and Hendrickson, 1993) , together with GDF9 as the closest homolog (Dube et al., 1998) . Like other TGFb members, this molecule is first translated as a pre-pro-peptide with an N-terminal signal peptide followed by the pro-domain and the C-terminal mature domain that conveys the biological activity . After removal of the signal peptide, the pro-protein dimerizes and is further cleaved at a conserved RXXR site by proconvertases, such as furin Hashimoto et al., 2005) . The specific functions of the pro-domains of TGFb superfamily members are largely unknown. The proteolytically processed pro-and mature regions of several GDFs/BMPs remain as a non-covalently-bound complex usually interacting with the extracellular matrix components (Sengle et al., 2011) . Concerning the BMP15 pro-region, it drives the dimerization and subsequent secretion of the mature dimers (Hashimoto et al., 2005) and may help to stabilize the mature region bioactivity (Pulkki et al., 2011) . Among 24 mammalian species, we detected signals of positive selection in the hominidae clade corresponding to residues in the human BMP15 pro-region (Auclair et al., 2013) . By replacing the positively selected amino acid either by alanine or the most represented residue in other studied species, some variants showed a significant increase of BMP15 signaling when compared with wild type. Therefore, some pro-region residues under positive selection are of great importance for the normal function of the protein and thus for female fertility.
A proteomic analysis indicated that several BMP15 regions are affected by post-translational modifications such as phosphorylation on Ser residue and N-or O-glycosylation on Asn or Thr residues, respectively (Saito et al., 2008 ). An unusual structural feature of BMP15, as well as of its paralog GDF9, is the lack of the cysteine residue in the mature domain required for the formation of covalent dimers (McPherron and Lee, 1993; Laitinen et al., 1998) . However, it has been demonstrated that BMP15 and GDF9 can form biologically active non-covalent homodimers when expressed individually (Liao et al., 2003 (Liao et al., , 2004 (Fig. 1) . The processed mature region of the secreted BMP15 protein forms a complex with the Ser/Thr kinase BMP receptor type II (BMPR2) and type I activin receptor-like kinase ALK6 (BMPR1B) on the membrane surface of GCs (Moore et al., 2003; Pulkki et al., 2012) . Alternatively, ALK3 (BMPR1A) was also demonstrated to be a mediator of BMP15 signaling in human GCs (Chang et al., 2013) . In contrast, GDF9 interacts with the known BMPR2 (Vitt et al., 2002) BMP15 expression is regulated by a sort of inhibitory feedback loop implicating Kit Ligand (KITLG)/KIT signalling and by GCNF. After removal of the signal peptides, the pro-proteins form non-covalent homo-or heterodimers with growth differentiation factor (GDF)9 products. After secretion in the follicular fluid, pro-regions are cleaved by furin (or furin-like enzymes), thus releasing the dimeric mature ligands. The effects of BMP15 on target cells can be modulated by the formation of BMP15:GDF9 heterodimers and by the binding protein follistatin (fs). The array of positive or inhibitory BMP15/GDF9 actions on GCs is dependent upon binding of the mature homo-or heterodimers to specific type 1 and type 2 transmembrane bone morphogenetic protein receptors (BMPR1 or BMPR2, respectively) coupled to the phosphorylation of SMAD proteins in target cells. Part of the variability in BMP15/GDF9 action may be due to the recruitment of different combinations of these receptors, and consequent activation of different intracellular pathways. FSHR, FSH receptor; GCNF, germ cell nuclear factor; IVM, In vitro maturation.
Nevertheless, since alk5 mutant mice have normal follicular development and cumulus expansion (Li et al., 2011) in contrast with gdf9 2/2 mice (Dong et al., 1996) , ALK5 is probably not the only physiologic type I receptor for GDF9. The downstream signaling pathway of BMP/ GDF factors involves the phosphorylation of intracellular signaling molecules called Smads, which then translocate to the nucleus and regulate target gene transcription . BMP15 treatment of GCs causes a clear increase in the levels of phosphorylated (activated) Smad1/5/8 (Moore et al., 2003) , whereas GDF9 specifically activates Smad2 protein phosphorylation (Kaivo-Oja et al., 2003) .
BMP15 biological action, with and without GDF9
As stated above, due to the lack of an important Cys residue, the in vitro production of recombinant BMP15 and GDF9 has helped to solve the question of the possible dimerization but also the bioactivity of those molecules. Despite heated discussion about the best biologically active recombinant molecule (tagged versus non-tagged, a purified versus enriched preparation) and on the species-specific issue of these different preparations (discussed in Mottershead and Watson, 2009) , convergent data emerge. Using a recombinant molecule originating from different species and obtained from different methods, BMP15 has been shown to increase the proliferation of GCs from rats (Otsuka et al., 2000) , humans (Di Pasquale et al., 2004) and ruminants (McNatty et al., 2005c) (Fig. 1) . Additionally, BMP15 is potent in stimulating GC mRNA for KITLG, a factor that is necessary for oocyte growth in preantral follicles. In return, KITLG inhibits BMP15 expression within the oocyte. It can be thought that the dialog between BMP15 and KITLG plays an important role in early follicular growth (Otsuka and Shimasaki, 2002) . When applied to mice pre-antral follicles cultured in vitro, BMP15 is potent in stimulating follicular growth, and in the same study was also shown to promote GCs apoptosis (Fenwick et al., 2013) . In later stages, BMP15 is able to modulate steroidogenesis of GCs. Indeed, in the rat, BMP15 selectively modulates the biological effects of FSH on GCs by inhibiting FSH-induced progesterone production without affecting FSH-induced estradiol synthesis (Otsuka et al., 2000) . The underlying mechanism implies the down-regulation of the FSH receptor (Otsuka et al., 2001) leading to the suppression of expression of numerous FSH-dependent genes such as steroidogenic acute regulatory protein (STAR), P450 sidechain cleavage enzyme (P450scc/CYP11A1), 3b-hydroxysteroid dehydrogenase (3b-HSD/HSD3B1), LH receptor and inhibin/activin subunits . In the sheep, BMP15 also suppresses basal and FSH-induced progesterone secretion by GCs from small antral follicles (Fabre et al., 2006) . Recently, a BMP15 inhibitory action on progesterone secretion through STAR down-regulation in human GC lines has been shown (Chang et al., 2013) . Moreover, BMP15 has been shown to control the expression of genes implicated in cumulus metabolism (Su et al., 2008; Caixeta et al., 2013) and expansion , and to increase oocyte developmental competence (Hussein et al., 2006) . Collectively, these data indicate that BMP15 is implicated all along the folliculogenesis process. It controls the early steps of follicular growth closely linked to GC proliferation. In later stages of follicular development, BMP15 might modulate the differentiative effect of FSH and control follicular maturation. Finally, BMP15 would also act on post-ovulatory processes, such as cumulus expansion and oocyte competence (Fig. 1 ). GDF9 and BMP15 were described to generate some opposite effects on GCs or theca cells in different species (reviewed in Shimasaki et al., 2004) , but it is nowadays accepted that many BMP15 biological actions within the ovary are mimicked by GDF9, or conversely (Otsuka et al., 2011) . Indeed, recombinant GDF9 is potent in stimulating initial follicle growth (Vitt et al., 2000b) , stimulating the proliferation of GCs and inhibiting FSH-induced steroidogenesis in GCs (Vitt et al., 2000a; McNatty et al., 2005c) . GDF9 also enhances cumulus expansion (Elvin et al., 1999; Gui and Joyce, 2005) and increases oocyte developmental competence (Hussein et al., 2006; Yeo et al., 2008) . Thus, it is important to consider the possible redundant or synergistic action of BMP15 and GDF9. Double knock-out mice models gave the first piece of evidence of a biological co-operation between these two oocyte-derived factors (Yan et al., 2001) . Finally, two options are submitted for debate to illustrate this concept (Mottershead et al., 2013; Peng et al., 2013) : the existence of a biologically active BMP15:GDF9 heterodimer and/or the synergistic co-operation of BMP15 and GDF9 homodimers (Fig. 1) .
Indeed, BMP15:GDF9 heterodimers are produced when co-expressed (Liao et al., 2003) and, in vitro evidence elucidated the physiological relevance of these heterodimers both in humans and in mice. Peng et al. (2013) described that mouse GDF9:BMP15 heterodimer is c. 10-to 30-fold more biopotent than mouse GDF9 homodimer, and human GDF9:BMP15 heterodimer is c. 1000-to 3000-fold more bioactive than human BMP15 homodimer. Concerning the signaling pathway, the nature of the interactions between heterodimers and type I and II receptors is still not completely resolved; however, the involvement of a BMPR2:ALK4/5/7:ALK6 complex followed by SMAD2/3 phosphorylation as the signaling mediator of the GDF9:BMP15 heterodimer has been proposed recently (Peng et al., 2013) , as previously hypothesized .
In parallel, a synergistic co-operation between BMP15 and GDF9 homodimers has been demonstrated. BMP15 and GDF9, even originating from different species, when given together are more potent than each growth factor alone in stimulating thymidine incorporation, inhibin production and inhibiting FSH-stimulated progesterone secretion by rat or ruminant GCs (McNatty et al., 2005b, c; Mottershead et al., 2012) . Interestingly, the BMP15 pro-region could regulate this cooperative interaction between BMP15 and GDF9 (McIntosh et al., 2008) . Moreover, the co-operation of GDF9 with BMP15 is essential to maintain the BMP15 stimulating effect on follicular growth of mice preantral follicles cultured in vitro (Fenwick et al., 2013) . In addition, GDF9/ BMP15 co-operation also activates SMAD2/3 as the major signaling pathway in GCs . Nevertheless, non-SMAD signaling pathways, such as nuclear factor kB, p38MAPK, extracellular signal-regulated protein kinase 1-2 or SRC kinase, are also implicated in the BMP15/GDF9 co-operative action on rodent GC thymidine uptake (Reader et al., 2011; Mottershead et al., 2012) .
BMP15 and oocyte competence in vitro
Oocyte competence is defined as the ability of the oocyte to complete maturation, undergo successful fertilization and reach the blastocyst stage (Assidi et al., 2008) . Many factors, such as the level of follicular atresia and the influence of the dominant follicle, may affect oocyte competence during follicular development (Hagemann, 1999) . Another example is given by oocytes originating from larger follicles that are more likely to reach the blastocyst stage than those from small follicles (Lonergan et al., 1994) . Moreover, it is well established that the bidirectional communication between the oocyte and the surrounding cumulus cells is essential for the development of a competent oocyte, along with the oocyte growth and maturation (Eppig, 2001) , further supported by in vitro culture of denuded bovine oocytes which considerably decreases their competence (Tanghe et al., 2002) . Physical communication between the oocyte and cumulus cells is mainly mediated through gap junctions formed by connexins (CX), which permit the transfer of metabolites for growth and development (Sugiura and Eppig, 2005) and also play an important role in the maintenance of meiotic arrest of the oocyte (Edry et al., 2006) . In particular, CX43 (GJA1) and CX45 (GJC1) have been identified between GCs (Gittens and Kidder, 2005) , and CX37 (GJA4) between GCs and the oocyte (Veitch et al., 2004) . In addition, the oocyte itself secretes into the follicular fluid (FF) and paracrine growth factors able to regulate a broad range of granulosa and cumulus cell functions, including GC proliferation (Vanderhyden et al., 1992; Gilchrist et al., 2001; Eppig et al., 2002) , prevention of apoptosis (Hussein et al., 2005) , modulation of steroidogenesis (Vanderhyden et al., 1993) , cumulus expansion (Buccione et al., 1990) , inhibin, activin and follistatin synthesis (Glister et al., 2003) , modulation of GC KITLG mRNA levels (Joyce et al., 1999) , inhibition of luteinization by suppressing LH receptor mRNA (Eppig et al., 1998) and urokinase plasminogen activator expression (Canipari et al., 1995) , thus actively regulating the follicular microenvironment. The molecular basis of the paracrine communication axis from oocytes to granulosa and cumulus cells is still emerging. However, a growing body of evidence has shown that the paracrine factor BMP15, as well as GDF9, regulates the essential follicular GC functions mentioned above. In fact, exposure of the maturing cumulus -oocyte complex to recombinant exogenous BMP15 and/or GDF9 dramatically increases their development to the blastocyst stage, thus proving that these oocyte-derived growth and differentiation factors are able to mimic the actions of the oocyte on granulosa and cumulus cells enhancing oocyte developmental competence during in vitro maturation (Hussein et al., 2006; Lin et al., 2013) .
BMP15 in experimental and natural models

Sheep
The identification of variation in the BMP15 gene as the genetic cause of ovarian phenotype defects was first shown in sheep and established the importance of BMP15 in female fertility. The Inverdale and Hanna sheep each carry naturally occurring mutations in BMP15 (p.V299D/FecX I or p.Q291X/FecX H ; Fig. 2 ) that cause increased ovulation rate and litter size in heterozygotes, but POF and blockage of folliculogenesis at the primary stage in homozygotes (Galloway et al., 2000) . This latter phenotype highlights the crucial role of BMP15 in controlling the transition to secondary follicle formation. This ovarian hypoplasia is associated with hypergonadotropism and low circulating levels of inhibin (McLeod et al., 1997; Smith et al., 1997) . To date, a total of six different natural 'loss-of-function' mutations, two in the pro-region and four in the mature domain, exhibiting this phenotype have been described (Fabre et al., 2006; Persani et al., 2011) Figure 2 Schematic illustration of the known BMP15 and GDF9 variants identified in sheep with alterations in the ovulation rate and fertility. The variants enclosed in black boxes induced hyperprolificacy in the heterozygous state, but sterility in the homozygous state due to a blockade of folliculogenesis at the early stages. The variants enclosed in red boxes enhanced the ovulation rate in a dose-dependent manner from the heterozygous to the homozygous state. The functional impact predicted by the nature of the variation or by the in vitro studies is also reported. Amino acid positions are given relative to ovine BMP15 (NP_001108239) and ovine GDF9 (NP_001136360) sequences. SP, signal peptide.
when individually expressed, both BMP15 mutations had no effect on the processing, secretion and dimerization of the mature proteins or on the biological activity of the molecules. However, the co-expression of mutant BMP15 and wild-type GDF9 significantly reduces the secretion of both factors, suggesting that the mechanism by which the BMP15 mutations affect sheep fertility involves also GDF9 activity (Liao et al., 2003 (Liao et al., , 2004 . Interestingly, mutations in the GDF9 gene (p.S395F, FecG H and p.S427R, FecG T ) (Fig. 2) on chromosome 5 likewise cause increased ovulation rates in heterozygous ewes and infertility in homozygous carriers, also with a blockage at early stages of folliculogenesis and hypergonadotropism McNatty et al., 2005a; Nicol et al., 2009) . Similar to BMP15, other mutations affecting GDF9 (p.F345C, FecG E and p.V371M, FecG WN ) lead to hyperprolificacy and not sterility in the homozygous state (Silva et al., 2011; Våge et al., 2013) . A deletion in the coding sequence of bovine BMP15 causing a frameshift and the generation of a stop codon was detected in five breeds in the heterozygous state (Zhang et al., 2009 ), but no hyperprolificacy phenotype was seen in cattle in contrast to sheep.
The immunization approaches led by the group of Juengel in New Zealand demonstrated the possibility that BMP15 and GDF9 could represent therapeutic targets to control fertility. Indeed, the effect on ovulation rate and sterility can be reproduced in sheep and cattle through adapted immunization regimens, neutralizing more or less BMP15 or GDF9, and confirms the crucial role of these two factors (Juengel et al., 2002 (Juengel et al., , 2004 (Juengel et al., , 2009 McNatty et al., 2007) .
Mice
In mice also, this immunization approach leads to the conclusion that BMP15 is important in the control of the ovulation rate in this polyovulatory species . However, unlike the mutated BMP15 homozygous ewes, bmp15 null female mice are not sterile but only subfertile with decreased ovulation and fertilization rates and minimal ovarian histopathological defects (Yan et al., 2001) . Thus, it is hypothesized that BMP15 associated with increased ovulation rate when altered in mono-ovulating sheep seems to be dispensable in polyovulating mouse. Consistently, Bmp15 mature form was barely detectable in the mouse ovary (Yoshino et al., 2006) likely due to a hampered pro-protein processing, as shown by several in vitro studies (Hashimoto et al., 2005; Al-Musawi et al., 2013; Peng et al., 2013) . Moreover, overexpression of a humanized biologically active form of Bmp15 in mice leads to accelerated folliculogenesis and causes an early decline in ovarian reserve. Therefore, an impaired production of biologically active Bmp15 during folliculogenesis in the wild-type mice may be relevant to their polyovulatory nature . However, such an assertion should be taken with caution since Bmp15 mature form was detected in mouse fetal ovaries (Guéripel et al., 2006) , and when produced after molecular engineering, Bmp15 mature form exhibited a detectable biological activity (Al-Musawi et al., 2013) .
As stated before, the functional interaction between BMP15 and GDF9 was first demonstrated in mouse models. Double homozygote females (bmp15 2/2 gdf9 2/2 ) look like gdf9 knock-out mice, which are infertile due to a blockade in folliculogenesis at the primary follicle stage. In contrast, bmp15 2/2 gdf9 +/2 female mice have more severe fertility defects than Bmp15 2/2 females, which appear to be due to abnormalities in ovarian folliculogenesis, cumulus cell physiology and fertilization (Yan et al., 2001 ).
Xenopus laevis
The role of BMP15 has also been investigated in Xenopus laevis embryos (Di Pasquale and Brivanlou, 2009 ). This study unveiled a new potential action of this factor in early embryo specification, showing BMP15 as a double inhibitor, blocking conventional BMP/GDF as well as Wnt ligands. The mechanisms behind the BMP15 'split personality' have not been completely clarified yet. The simplest explanation relies on a diverse function in the two different contexts, the embryo and the oocyte/GC circuit. Alternatively, it has been proposed that BMP15 forms gradients emanating from the cells surrounding the oocyte that correspond to different outcomes, producing opposite responses in different cell types depending on the expression of cell type-specific receptors and co-factors. The balance between activating and inhibitory inputs, provided by both TGF and BMP ligands and other secreted inhibitors (such as noggin, chordin, follistatin, lefties and Coco) that act at different times and regions of the embryos, provides the morphogen gradients driving early embryo development and regulating the specification of the three germ layers. Specifically, the interaction between BMPs and their inhibitors are involved in the fundamental decision between the induction of neural versus epidermal fate (Wilson et al., 1997; Hill, 2001; Kimelman and Pyati, 2005; Heasman, 2006) . BMP inhibitors, such as chordin, noggin and follistatin, are produced in the dorsal side of the embryo by the region called the 'Spemann organizer' and are able to block the BMP gradient that originates from the ventral side, creating different levels of BMP signaling along the dorsal-ventral axis of the embryo (Munoz-Sanjuan and Brivanlou, 2002; Stern, 2005) . How perturbation of such a system reflects on embryo phenotype is well understood and can lead to a functional characterization of the molecules involved in this signaling pathway (Vonica and Brivanlou, 2007; Bates et al., 2013) .
By virtue of those features, the Xenopus model can constitute a good platform to functionally evaluate how, and to what extent, BMP15 mutations affect the protein function. BMP15 (and GDF9) protein shares characteristics with other TGFb factors that have been shown to have an inhibitory effect on the pathway and to induce a neural phenotype when injected into the part of the embryo fated to become epidermis (animal pole) (Munoz-Sanjuan and Brivanlou, 2002) . Injection of the human p.Y235C-BMP15 RNA in the animal pole of a 2-cell stage embryo has been shown to abolish the inhibitory activity of BMP15, indicating the loss of function of the protein due to this specific mutation (Di Pasquale and Brivanlou, 2009 ). Data from this study confirm that, even though not physiologically relevant for ovary development and function, such a model can be used to test the consequences of new mutations on BMP15 and GDF9 function.
Hen (Gallus gallus domesticus)
Few studies have been undertaken on BMP expression and their roles in hen ovaries; studies mainly focused on BMP4 and BMP7 (Onagbesan et al., 2003) and GDF9, which was expressed in hen oocytes and also present at lower levels in GCs where it exerts a mitogenic effect (Johnson et al., 2005) . However, most of the presumptive ovarian roles of BMPs remain unexplored in birds. In the hen, RT -PCR and in-situ hybridization analyses indicated that BMP15 is predominantly expressed in the ovary and its presence is limited to the oocyte (Elis et al., 2007) . At the functional level, it has been shown that the recombinant human BMP15 (rhBMP15) was able to strongly decrease LH-induced progesterone production from GCs of large maturing pre-ovulatory follicles, associated with a marked decrease in STAR expression. Together with the capacity to phosphorylate Smad1 in cultured GCs, these data suggested the bioactivity of human BMP15 in the hen. Interestingly, in contrast to mammals, we found the absence of effect of rhBMP15 on hen GC proliferation. Possible explanations were the relatively low percentage of identity (72%) between the human and hen BMP15 sequence, or the requirement of GDF9:BMP15 heterodimers to exert a biological effect on proliferation of hen GCs (Elis et al., 2007) .
Zebrafish (Danio rerio) Clelland et al. (2006) have cloned the zebrafish BMP15 (zfBmp15) cDNA and described the genomic organization of zfBmp15 in two exons and one intron, located on chromosome 6. By phylogenetic analysis, the zfBmp15 mature domain has shown 46-55% sequence identity to BMP15 of fish, bird and mammals. Moreover, zfBmp15 resembles tetrapod BMP15 and GDF9, possessing only six cysteines in the mature region. By in situ hybridization and immunocytochemistry, positive signals for an ovarian expression pattern of zfBmp15 were observed both in oocytes and follicular somatic cells throughout different stages of follicle development (Clelland et al., 2006) . In contrast, the zebrafish GDF9 (zfGdf9), which shares 60% identity with that of mammals in the mature region, is mainly expressed in the oocytes, as barely detectable amounts of mRNA were detected in cultured zebrafish follicular cells that were free of oocytes (Liu and Ge, 2007) . The zfGdf9 exhibits an expression pattern strongly stage dependent during follicle development, with the highest mRNA levels in the primary growth follicles, and gradually decreasing with follicle development, inversely to LH/ CG receptor expression. This suggests a potential involvement of the pituitary gonadotrophin in the determination of the decreasing expression of GDF9 that occurs during zebrafish follicle growth (Liu and Ge, 2007) . Moreover, GDF9 was described to modulate tight junction integrity within follicles, possibly facilitating the ovulation process (Clelland and Kelly, 2011) .
The functional role of zfBmp15 has been investigated by incubating zebrafish follicles with rhBMP15 in which treatment with hCG failed to induce oocyte maturation, thus indirectly suggesting that BMP15 has an inhibitory effect on oocyte maturation (Clelland et al., 2006) . In a following study, the authors further investigated the role of BMP15 by both 'loss of function' and 'gain of function' approaches using an antiserum developed for zfBmp15, and by microinjection with either antisense zfBmp15-N-morpholino oligonucleotides or a construct containing zfBmp15 cDNA, respectively (Clelland et al., 2007) . Both incubation with antiserum and the zfBMP15 knockdown resulted in increased oocyte maturation, whereas overexpression of BMP15 cDNA in oocytes significantly reduced maturationinducing hormone-and hCG-induced oocyte maturation in normally competent, mid-growth-phase follicles. Collectively, this confirmed the previous findings and provided novel in vivo evidence suggesting that BMP15 mainly acts on early growth phase follicles to inhibit their growth and premature maturation.
Role of BMP15 in human fertility
Turner syndrome TS is one of the most common chromosomal anomalies with a prevalence of 1:2500-1:3000 female births (Sybert and McCauley, 2004) . Affected individuals exibit a variable spectrum of physical and functional alterations likely due to a wide variety of karyotype abnormalities, ranging from 45,X monosomy to various forms of 45,X/46,XX mosaicism with or without structural defects of the X chromosome in the euploid cell line (Sybert and McCauley, 2004) . The pathogenesis of TS is intricate but because several X-linked genes escape X chromosome inactivation, it is conceivable that the monosomy for distinct genes may account for the common phenotypic manifestations of TS (Zinn and Ross, 1998; Persani et al., 2009) . Indeed, this is the case for short stature and skeletal features of TS that are caused by haploinsufficiency for the SHOX gene, which is located in the pseudoautosomal region in Xp. Studies of the X chromosome breakpoints revealed the existence of two distinct loci on the Xq (Xq13-q21 and Xq23-q27) and one region on the Xp22.1-p11.2 that were significantly associated with the ovarian defect (Toniolo, 2006; Persani et al., 2009) . Nevertheless, spontaneous puberty can be observed in 25% of TS patients and more frequently among mosaics (Pasquino et al., 1997; Gracia Bouthelier et al., 2004; Martin Campagne, 2009 ), thus inversely correlating with the severity of chromosomal anomalies at conventional karyotype. The BMP15 gene maps on the short arm of the X chromosome (Xp11.2), within one of the 'POF critical regions' (locus POF4; MIM number 300510) (Zinn and Ross, 1998; Persani et al., 2009) . Very recently, we performed a high-resolution comparative genome hybridization (CGH)-array analysis in a cohort of TS patients with or without spontaneous menarche (Castronovo et al., 2013) . Surprisingly, we identified a tandem duplication of the single BMP15 gene in an 11-year-old patient with 45,X karyotype, who caught pediatrician's attention because of a short stature, and who experienced a spontaneous menarche followed by regular menses for .4 years. Consistent with the SHOX haploinsufficiency and despite growth hormone treatment this patient is short (145 cm at 34 years), but the BMP15 duplication on the conserved X chromosome might have preserved a sufficient gene dosage in the developing ovary during the first meiotic phases, when a double dose of X-linked genes should be required. This BMP15 duplication would have led to the conservation of a certain amount of functional follicles at pubertal age and the ability to compensate, at least partially, for the loss of one copy of the other X-linked genes. Accordingly, by means of FISH and CGH array we identified the presence of a mosaicism with the euploid cell line .10% in the other five TS patients with spontaneous menarche of our cohort (Castronovo et al., 2013) . Taken together, these data confirm that BMP15 gene dosage contributes to the ovarian phenotype of TS patients, and support the hypothesis that BMP15 represents the first ovary-determining gene to be identified on the X chromosome (Layman, 2006) . This finally brings additional support to the idea that inactivating mutations in this gene can predispose to POI.
POI
Missense mutations in the BMP15 gene have been identified in association with primary or secondary amenorrhea in several cohorts of women affected by POI (Persani et al., 2010) . The first mutation in the human BMP15 gene was reported in two 46,XX Italian sisters with primary amenorrhea and ovarian dysgenesis, who inherited the variant from their hemizygous father. This mutation causes the substitution p.Y235C lying in the pro-region of the protein (Fig. 3) (Di Pasquale et al., 2004) . The addition of a supplementary Cys residue is associated with the generation of aberrant high-molecular weight product in vitro, as observed with western blotting. The recombinant mutant BMP15 was evaluated through a bioassay on primary cultures of human GCs and showed an impairment of the growth stimulatory activity. In contrast, the p.Y235C mutation increased the BMP15 Smad-dependent signaling in a novel bioassay, and the inhibition of progesterone secretion by GCs (Auclair et al., 2013) . Experiments of co-incubation of wild-type and p.Y235C mutant further characterized the effect of the mutant, consistent with a mechanism of negative dominance on the wild-type BMP15. Subsequently, additional variants were identified with a variable frequency in 46,XX patients from Japan, New Zealand, Europe, USA, North Africa, India, China and other Asian countries (Table I) (Takebayashi et al., 2000; Chand et al., 2006; Di Pasquale et al., 2006; Dixit et al., 2006; Laissue et al., 2006; Zhang et al., 2007; Ledig et al., 2008; Rossetti et al., 2009; Tiotiu et al., 2010; Wang et al., 2010; Ferrarini et al., 2013) . Almost all these variations are missense and found in the heterozygous state and are also located in the gene sequence encoding the pro-region of the protein. Among all the identified variations, only one, in an Indian woman with primary amenorrhea and ovarian dysgenesis, was found to cause a premature truncation of the protein (Dixit et al., 2006) . This heterozygous variation creates a premature stop in the pro-region (p.E211X) resulting in the translation of a protein lacking the mature BMP15 peptide, thus producing a haploinsufficiency for the BMP15 gene (Fig. 3) .
Putting the results from all these studies together, we found that the prevalence of non-synonymous mutations in the POI cohorts is 10-fold higher than in the control populations (P , 0.0001 by Fisher's exact test), thus supporting the pathogenic role of these rare variants. Unfortunately, studies of the co-segregation with the POI phenotype in families are scanty and difficult to perform in an infertility disorder. Therefore, we engineered a novel BMP-responsive luciferase-reporter assay allowing the functional analysis of BMP15 variants in a human GC line . Several missense variants of the human proregion of BMP15 displayed an impaired post-translational processing of the pro-proteins, causing a significant reduction in bioactive protein production (Fig. 3) . Also in this case, the in vitro analysis of these variants showed an impairment of BMP15 function generally consistent with a haploinsufficiency mechanism (Rossetti et al., 2009 ). The only missense substitution located in the mature peptide region identified so far was in a Chinese woman with POI with a family history of early menopause (Wang et al., 2010) . Involving an Arg to Cys amino acid change at residue 329 (p.R329C), this variant probably alters the structure of BMP15 by impairing the correct folding of the protein and causes a significant reduction in the biological activity. Moreover, co-transfection with wild-type plasmids, reproducing the heterozygous situation in vivo, failed to completely restore the normal transcriptional activity (unpublished data). Cytofluorometry assay of cells stably expressing p.R329C was further performed to evaluate the pro-protein cellular content. This analysis showed reduced levels of the variant in comparison with the wild type (unpublished data). More recently, in agreement with the haploinsufficiency hypothesis, a deletion of 4 Mb at Xp11.23 -p11.22, including BMP15, has been identified in a POI patient by singlenucleotide polymorphism (SNP) array analysis (McGuire et al., 2011) . Altogether, these data support the view that a double dose of the BMP15 gene should be required for the determination of an adequate ovarian follicle reserve in women.
By analyzing the data coming from all the studies in POI women, BMP15 variants showed a prevalence of 0-12% among different ethnicities (Table I) . Therefore, the loss-of-function BMP15 variations constitute one of the more frequent events giving an increased susceptibility risk to premature ovarian ageing and supporting the genetic origin of POI (Persani et al., 2010) . Nevertheless, further studies are required to fully understand their functional implications and whether they constitute one predisposing event, requiring the combination with other genetic or environmental factors to generate the full blown POI phenotype.
Similarly to BMP15, the first mutational screening of the GDF9 gene was performed in a Japanese cohort of 15 infertile women with 46,XX POI, but no mutations were found (Takebayashi et al., 2000) . Lack of sequence variation in the GDF9 gene was also observed in a larger and predominantly Caucasian population (n ¼ 38) with POI (Chand et al., 2006) . Conversely, heterozygous mutations of GDF9 have been described in the Indian, French, North American and Chinese populations with POI. Two novel rare mutations (p.K67E and p.V216M) affecting the pro-region of GDF9 were found in a total of seven Indian cases, but were absent in the control population (Dixit et al., 2005) and poorly expressed in in vitro experiments (Inagaki and Shimasaki, 2010; Simpson et al., 2014) . Another missense mutation affecting the proregion of GDF9 was identified in a French patient of Caucasian origin with secondary amenorrhea, leading to the change p.S186Y, with a potential pathogenic effect as predicted by in silico analysis (Laissue et al., 2006) . Moreover, the replacement of the nonpolar amino acid Proline with the polar amino acid Serine at position 103 within the GDF9 proregion was identified in a Caucasian woman with 46,XX POI from North America (Kovanci et al., 2007) and causes the abrogation of mature peptide expression (Simpson et al., 2014) . In the Chinese population, the substitutions p.T238A and p.R146C were detected in POI patients and not reported in the control populations (Zhang et al., 2007; Wang et al., 2013) . The molecular and functional studies show that the p.R146C substitution causes a significant reduction in GDF9 mature protein secretion in cultured cells and diminishes the ability of GDF9 to stimulate GC proliferation and to activate the Smad2 pathway . On the contrary, the other variants located at the C-terminus of the pro-domain (p.S186Y, p.V216M and p.T238A) significantly increase GC proliferation in a dose-dependent manner. Probably, these variants affect the stability of the latent GDF9 complex, rather than increase the activity of mature GDF9. In fact, the mature domains of these variants, obtained from a two-step purification protocol, show a biological activity similar to the wild-type GDF9 in a GC proliferation assay (Fig. 3B) (Simpson et al., 2014) . 
PCOS
Due to its role in folliculogenesis, several studies focused on the involvement of BMP15 in PCOS pathogenesis. A couple of studies investigated the frequency of BMP15 variations in patients with PCOS. No variations were identified in 38 Japanese subjects (Takebayashi et al., 2000) , whereas 5 new missense variants (p.L12V, p.A37P, p.P57A, p.R96S and p.Y200H) were identified in 216 Chinese patients (Liu et al., 2011) . Nevertheless, no functional study was performed. Another study failed to find an association of particularly frequent SNPs (29C.G and IVS1+905A.G) of BMP15 with PCOS in Spanish women, but did claim an association of both markers with anovulation and infertility (Gonzalez et al., 2008) . More recently, a series of Caucasian women with and without PCOS (335 cases, 198 controls) were genotyped for SNPs in GDF9, BMP15, anti-Mullerian hormone (AMH) and AMHR2, but variants in these genes were not associated with PCOS or anovulation phenotypes (Sproul et al., 2010) (Table I ). These data indicate that the actual involvement of BMP15 genetic variations in PCOS pathogenesis remains controversial. After a negative screening in a cohort of 38 Japanese patients (Takebayashi et al., 2000) , the genetic analysis of 216 Chinese patients with PCOS revealed 5 novel missense mutations in GDF9-coding sequence (p.N5L, p.L40V, p.M45V, p.Y342F, p.S425R) that were absent in 200 controls (Wang et al., 2010) . Molecular studies demonstrated an impaired expression for the p.Y342F and p.S425R substitutions (Simpson et al., 2014) . However, despite the lower expression, the two variants located within the mature domain affect GDF9 bioactivity by increasing the affinity for its signaling receptors, as assessed by [3H]thymidine incorporation in mural GCs (Fig. 3B) (Simpson et al., 2014) . Finally, the remaining variants were predicted to be benign. This study indicates that GDF9 variants may be associated with the development of PCOS. Nevertheless, the actual involvement of BMP15 and/or GDF9 expression dysregulation in the etiology of PCOS is still a matter of debate (Teixeira Filho et al., 2002; Wei et al., 2011) .
Dizygotic twinning
The BMP15 gene variants previously identified in women with POI (n ¼ 17) together with 14 common variants and 4 rare variants have been also studied in 933 families with a history of spontaneous multiple pregnancies (Zhao et al., 2008) , as dizygotic (DZ) twinning would be the feature corresponding to the hyperprolificacy phenotypes of sheep carrying heterozygous BMP15 or GDF9 variants Persani et al., 2011) . Three of the four rare BMP15 variants (p.P174S, p.A311T and p.R392T) occurred in few mothers of DZ twins but were not detected in 1512 controls. Though weak effects or epistatic interactions with other variants could not be ruled out, the authors found no evidence that either rare or common variants in BMP15 play any significant role in the variation in human DZ twinning.
A four base pair deletion in GDF9, which introduces a stop codon 18 amino acids downstream, was first identified in two sisters with spontaneous DZ twins (Montgomery et al., 2004) . The deletion was inherited from the father, hence, the mutation could not account for the increased rate of twins in the maternal branch of the family. To investigate if rare mutations in GDF9 may contribute to an increased frequency of twins in more families, the same authors subsequently performed a screening for GDF9 variants in 915 families with a history of DZ twinning (Palmer et al., 2006) , which led to the identification of six new variants within the GDF9 coding region (Fig. 3B) . The variants c.1268-1269delAA and p.P374L were not observed in the control population, and the frequency of the variants in GDF9 in mothers of twins was twice the frequency in the controls (P ¼ 0.0001). Very recent molecular studies have shown that the p.P374L variant completely abrogates the GDF9 mature domain expression, while the p.R454C variant reduces the expression of the mature protein (Fig. 3B) . Nevertheless, the p.R454C variant increases GC proliferation in the [3H]thymidine incorporation assay, suggesting an augmented affinity of mutant GDF9 for its signaling receptors (Simpson et al., 2014) . Interestingly, the GDF9 variant (p.P103S) associated with DZ twinning (Palmer et al., 2006) was subsequently reported also in one POI patient (Kovanci et al., 2007) . These data indicate that the relationship between DZ twinning and POI is worthy of further investigation.
IVF procedures
Many hormonal and ultrasound markers, such as basal serum FSH level, serum AMH level and the number of antral follicles, have been developed, depending on age, to predict the cycle success or identify patients at high risk of poor or high response. Some studies (de Resende et al., 2012; Wei et al., 2013) evaluated the variations in BMP15 (and GDF9) gene expression by real-time PCR in oocytes and GCs from women with or without PCOS, undergoing controlled ovarian stimulation (COS) or not. The Chinese group observed that COS could promote the expression of GDF9 and BMP15 both in oocytes and GCs from normal ovulatory women. However, the stimulating effects were diminished in oocytes from patients with PCOS. These data are apparently in contrast with those of the Spanish group that found higher BMP15 mRNA levels in oocytes from women with PCOS compared with controls. Discrepancies might be due to the limited number of cases enrolled and to the heterogeneous nature of the sampling; in addition, these authors did not correlate the results with COS outcome.
A few studies have been performed to assess a correlation between FF levels of BMP15 protein and oocyte development, fertilization outcome and early post-fertilization development. Wu et al. (2007) first estimated the BMP15 content in 79 FF samples from ICSI protocols by western blot analysis. Results show that a higher FF level of BMP15 significantly correlated with higher fertilization rate, better cleavage and better quality embryo development. Furthermore, BMP15 levels also showed a significant positive correlation with estradiol levels and a negative correlation with FSH concentrations in FF, demonstrating that the BMP15 level in FF appears to be a potential factor in predicting oocyte quality and subsequent embryo development. The same authors have recently extended the study to 207 poor ovarian responders undergoing IVF/ ICSI and FF BMP15 levels were compared with implantation, pregnancy and live birth rates. All the outcome measures were significantly augmented in the group with higher FF BMP15 levels. Furthermore, poor responders aged ≤35 years with a higher FF BMP15 level had implantation, pregnancy and live birth rates comparable to those of normal responders, suggesting a potential role for BMP15 in the prediction of IVF outcome in poor responders (Wu et al., 2012) . Another study was concurrently performed to evaluate the association of FF levels of BMP15 and GDF9 with subsequent oocyte and embryo quality in human IVF cycles. The expression levels of the pro-peptide and mature forms of FF GDF9 and BMP15 were determined by western blot analysis of the FF from a single follicle in 81 women undergoing IVF/ICSI. No significant relationship was found between fertilization and cleavage rates and the mean levels of both the pro-peptide and the mature forms of GDF9 and BMP15. However, a significant negative correlation between FF mature GDF9 and progesterone levels was detected (P , 0.05). In conclusion, an increased level of the mature form of FF GDF9 significantly correlates with the nuclear maturation of oocytes and quality of embryos. The divergent results on FF BMP15 with respect to previous studies may be due to the lack of the mature form of BMP15 in 39.5% of patients. However, patients have not been screened for BMP15 mutations, which might lead to impaired or decreased production of the protein. Discrepancies might also be due to a bias of sample selection and limitations of the analysis technique (Gode et al., 2011) .
One study evaluated the association of BMP15 gene variants with response to COS using FSH in 307 women (Moró n et al., 2006) . They found a particular haplotype that was over-represented in high responders when compared with the other patients. Moreover, this association was higher in patients with ovarian hyperstimulation syndrome, with a significant global haplotypic effect of the BMP15 gene, and thus suggesting a direct relationship between increased follicle production during COS and BMP15 alleles in response to FSH in humans. These results were confirmed in a more recent study highlighting the BMP15-9G allele (Hanevik et al., 2011) .
Conclusions and what is still missing
This review demonstrates the large interest dedicated to the role of BMP15 (and its partner GDF9) in female fertility. First highlighted by natural mutations affecting female fertility in animals and thereafter in humans, BMP15 has become an object of essential research in the study of ovarian function. Since 2000, numerous research groups have spent time and effort to create important tools (recombinant proteins, specific antibodies, animal models) to decipher the role of this oocytederived growth/differentiation factor on folliculogenesis and the effects on promoting follicle growth, maturation and finally ovulation rate. Remarkable efforts have been made to dissect the mechanisms of action of these oocyte growth factors, but further studies are required to solve the question of the functional interaction between BMP15 and GDF9: in many species with different ovulation rates their synergism or heterodimerization appears definitely more potent than the respective homodimers. Thus, it is now crucial to produce fully functional recombinant BMP15 and GDF9 proteins for each species of interest. Using these molecules, the identification of numerous natural mutants in BMP15 and GDF9 with effects on the ovine or human ovary will be a unique opportunity to dissect the molecular and functional interaction of both molecules in the control of female fertility. Some studies shed light on the few BMP15 target genes identified in GCs, but a comprehensive characterization of the BMP15 transcriptome in human GCs is still lacking, and such information would certainly bring interesting additional insights into BMP15 action and ovarian follicle pathophysiology.
The accumulated data indicate that BMP15/GDF9 activity may also become a target of novel pharmacological interventions, as the BMP activities on folliculogenesis can be modulated by treatment with the binding protein follistatin (fs) (Otsuka et al., 2001; Hussein et al., 2006) or with specific anti-BMP15 antibodies (Lin et al., 2012) . Following the immunization studies demonstrating a blockade of folliculogenesis in animals with a low ovulation rate (Juengel et al., 2004 (Juengel et al., , 2009 , the development of monoclonal antibodies blocking BMP15 activity might be fundamental in the generation of novel contraceptive tools for animal or human purposes. Conversely in the IVF context, the use of BMP15/ GDF9 stimulation may become part of standardized protocols for the promotion of follicular maturation and oocyte competence in vitro. PCOS may also represent another interesting field for future BMP15/ GDF9 research, as the modulation of BMP15/GDF9 activity may constitute novel targets for the treatment of the characteristic derangements in follicular maturation in these women.
In human pathology, the combination of results collected in POI and Turner subjects would point to BMP15 as the first gene identified on the X chromosome whose dosage is critical for the determination of ovarian reserve and age at menopause. The higher prevalence of BMP15 variants in patients with POI compared with the control population supports a pathogenic role for these variants. However, further studies should focus on the biological mechanism that would be disrupted by BMP15 loss-of-function and how this would be linked to the ovarian defect and early menopause.
Interesting new perspectives have also been generated from studies regarding the possibility of predicting COS outcome by analyzing BMP15 genotype. As in other pharmacogenetic studies, it is likely that a better level of prediction would be possible through the combined analysis of common and rare variants in a panel of candidate genes using next generation sequencing.
The results obtained in all of the studies reported here support BMP15 as a marker of oocyte quality. If this hypothesis is correct, the development of a BMP15 assay (such as a sensitive and reproducible enzymelinked immunosorbent assay) for follicular fluid would become pivotal in assisted reproduction procedures in order to select the oocytes with the highest chance of fertilization among those recovered after COS.
